

# Bemcentinib

**Catalog No: tcsc1046**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1037624-75-1

**Formula:**

$C_{30}H_{34}N_8$

**Pathway:**

Protein Tyrosine Kinase/RTK

**Target:**

TAM Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 10.25 mg/mL (20.23 mM; Need ultrasonic and warming)

**Alternative Names:**

R428;BGB324

**Observed Molecular Weight:**

506.64


## Product Description

Bemcentinib (R428) is a potent and selective inhibitor of **Axl** with an **IC<sub>50</sub>** of 14 nM.

IC50 & Target: IC50: 14 nM (Axl kinase)

**In Vitro:** Bemcentinib (R428) (2μM) significantly interferes with mechanisms of migration and invasion of Axlpos melanoma cells at levels comparable to Axl knockdown<sup>[1]</sup>. Bemcentinib (R428) synergizes with cisplatin to enhance suppression of liver micrometastasis<sup>[2]</sup>. Bemcentinib (R428) (50 nM-1μM) causes a concentration-dependent inhibition of preadipocyte differentiation into mature adipocytes, as evidenced by reduced lipid uptake<sup>[3]</sup>.

**In Vivo:** Bemcentinib (R428) (125 mg/kg, p.o.) significantly blocks MDA-MB-231-luc-D3H2LN metastases development in two independent mouse models of breast cancer dissemination, suppresses both tumor angiogenesis and vascular endothelial growth factor (VEGF)-induced corneal neovascularization in vivo<sup>[2]</sup>. Bemcentinib (R428) (75 mg/kg/day, 25 mg/kg twice daily, p.o.) makes mice keep on a high-fat diet resulted in significantly reduced weight gain and subcutaneous and gonadal fat mass<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!